All In Biotech

Drug Trial Radar · NCT03962855

Thromboxane Receptor Antagonist to Improve Endothelial Function

The Thromboxane Receptor Antagonist to Block the Effects of Non-Platelet Thromboxane Generation and Improve Endothelial Function (TRAP) Trial

Last checked: Nov 19, 2026Latest source record: Dec 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

57

Actual

Start

Sep 20, 2019

Primary completion

Nov 7, 2022

Study completion Nov 15, 2022

Sponsor

Lead sponsor
Jeffrey RadeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
American Heart Association; Cumberland Pharmaceuticals
First posted
May 24, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates whether addition of the thromboxane receptor antagonist to chronic aspirin therapy improves endothelial function and reduces non-platelet thromboxane generation in patients with established cardiovascular disease. Half of participants will receive ifetroban and the other half will receive matching placebo for the 4 week study period.

Conditions

  • Cardiovascular Diseases
  • Vascular Dilation

Interventions

  • Ifetroban SodiumDrug

    Ifetroban sodium 250 mg capsule once daily for 4 weeks

  • PlaceboDrug

    Placebo arm to match Ifetroban Sodium once daily for 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Reactive Hyperemia Index (RHI)Time frame: Baseline to 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Massachusetts Medical School

    Worcester, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.